london euretina

This meeting has been awarded 20 CME credits

Security Notice

Please note that Kuoni are our only destination management company. Other venders indicating that are operating for the society should be ignored. We never use western union as a payment portal

Earliest real-life experience using lucentis for macular edema secondary to branch retinal vein occlusion in the national health service (NHS)- bravo?

Session Details

Session Title: Quick Fire Free Paper 1

Session Date/Time: Thursday 11/09/2014 | 08:00-10:00

Paper Time: 08:00

Venue: Boulevard D

First Author: : J.J.Gonzalez-Lopez UK

Co Author(s): :    B. Arya   P. Addison           

Abstract Details


To describe the changes in best corrected visual acuity (BCVA) and optical coherence tomography (OCT)-measured central foveal thickness (CFT) in patients receiving their first course of 3 monthly injections of 0.5 mg Lucentis (ranibizumab) for macular oedema secondary to branch retinal vein occlusion (BRVO).


Single, tertiary-care hospital in central London (Moorfields Eye Hospital NHS Foundation Trust)


A retrospective, observational case series including 18 eyes of 18 patients with macular oedema following BRVO was performed. Patients having completed at least one month of follow-up after a course of 3 monthly 0.5 mg ranibizumab injections between September 1st 2013 and February 20th 2014 were included in the study. Patient records were reviewed by 2 of the authors, and data was recovered about their demographic characteristics (age, sex), time since the onset of the BRVO symptoms, previous treatments (laser, ozurdex), BCVA in each visit, OCT-measured CFT in each visit, need for further laser treatment and adverse events.


Mean +/- standard deviation (SD) change from baseline BCVA letter score at month 3 was 14.1+/-12.8 (Wilcoxon P=0.001). This is similar to what was observed in the BRAVO clinical trial (12-16 letter gain at month 3). Eight patients (44.4%) gained ≥15 letters in BCVA at month 3. This is similar to what was observed in BRAVO at month 3 (38.1-50.4%). Seven ranibizumab-treated patients (38.8%) had BCVA of ≥20/40 at month 3. The mean +/- SD reduction from baseline in CFT at month 3 was 210±107 µm (Wilcoxon P<0.001), less than what was observed in the BRAVO trial (275-375 µm reduction). The median percent reduction in excess foveal thickness at month 3 was 87.9%. No adverse events were observed in the 18 patients included in the study.


Intraocular injections of 0.5 mg ranibizumab provided rapid, effective treatment for macular edema following BRVO, with a change in BCVA similar to that observed in the BRAVO trial, although the anatomical reduction of CFT measured with OCT was smaller than that observed in the trial. No ocular and nonocular safety events were observed in this small sample of patients.

Back to previous
EURETINA, Temple House, Temple Road, Blackrock, Co Dublin. | Phone: 00353 1 2100092 | Fax: 00353 1 2091112 | Email:

Privacy policyHotel Terms and Conditions Cancellation policy